Published in Int J Hepatol on February 24, 2013
Histopathology of hepatocellular carcinoma. World J Gastroenterol (2014) 0.98
Liver masses: a clinical, radiologic, and pathologic perspective. Clin Gastroenterol Hepatol (2013) 0.81
Benign hepatocellular nodules of healthy liver: focal nodular hyperplasia and hepatocellular adenoma. Clin Mol Hepatol (2016) 0.77
Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA (2012) 33.54
Overweight and obesity in the United States: prevalence and trends, 1960-1994. Int J Obes Relat Metab Disord (1998) 11.96
Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology (2006) 5.46
Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature (2008) 5.38
Possible association between benign hepatomas and oral contraceptives. Lancet (1973) 3.98
Liver-cell adenomas associated with use of oral contraceptives. N Engl J Med (1976) 3.60
Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepatology (2007) 3.18
Epidemiology of hepatocellular adenoma. The role of oral contraceptive use. JAMA (1979) 2.99
Clinical practice. Combination estrogen-progestin oral contraceptives. N Engl J Med (2003) 2.41
Liver adenomatosis: re-evaluation of aetiology and management. Liver Int (2008) 2.30
Changing trends in malignant transformation of hepatocellular adenoma. Gut (2011) 2.28
P53 gene and Wnt signaling in benign neoplasms: beta-catenin mutations in hepatic adenoma but not in focal nodular hyperplasia. Hepatology (2002) 2.18
Management of 155 patients with benign liver tumours. Br J Surg (2001) 1.97
Validation of a liver adenoma classification system in a tertiary referral centre: implications for clinical practice. J Hepatol (2010) 1.91
Benign and solid tumors of the liver: relationship to sex, age, size of tumors, and outcome. Am Surg (2001) 1.72
Liver cell adenoma: a multicenter analysis of risk factors for rupture and malignancy. Ann Surg Oncol (2009) 1.44
Benign hepatic tumors: focal nodular hyperplasia and hepatocellular adenoma. World J Surg (1995) 1.35
Hepatic cell adenomas, spontaneous liver rupture, and oral contraceptives. Arch Surg (1975) 1.27
Selective management of hepatic adenomas. Am Surg (1996) 1.24
Hepatic tumors induced by sex steroids. Semin Liver Dis (1984) 1.21
Telangiectatic adenoma: an entity associated with increased body mass index and inflammation. Hepatology (2007) 1.21
Surgical management of hepatocellular adenoma: take it or leave it? Ann Surg Oncol (2008) 1.12
Systematic review of hepatocellular adenoma in China and other regions. J Gastroenterol Hepatol (2011) 1.09
Liver resection for hepatic adenoma. Arch Surg (1979) 1.09
Benign liver tumors: an update. Clin Liver Dis (2010) 1.07
Bland embolization in the treatment of hepatic adenomas: preliminary experience. J Vasc Interv Radiol (2011) 0.99
Characterization of hepatocellular adenoma based on the phenotypic classification: The Kanazawa experience. Hepatol Res (2011) 0.98
Hepatocellular adenoma subtypes: the impact of overweight and obesity. Liver Int (2012) 0.96
Clinical features and natural history of hepatocellular adenomas: the impact of obesity. Aliment Pharmacol Ther (2011) 0.87
Benign gynecological tumors: estimated incidence. Results of the German Cohort Study on Women's Health. Eur J Obstet Gynecol Reprod Biol (2003) 0.86
Multiple hepatic adenomas associated with liver steatosis at CT and MRI: a case-control study. AJR Am J Roentgenol (2008) 0.83
Hepatocellular adenoma in advanced-stage fatty liver disease. Eur J Gastroenterol Hepatol (2009) 0.81
Benign hepatocellular tumors (adenomatosis) in nonalcoholic steatohepatitis: a case report. Semin Liver Dis (2005) 0.80
Multiple inflammatory and serum amyloid A positive telangiectatic hepatic adenomas with glycogenated nuclei arising in a background of nonalcoholic steatohepatitis. Semin Liver Dis (2008) 0.77
Telangiectatic variant of hepatic adenoma: clinicopathologic features and correlation between liver needle biopsy and resection. Am J Surg Pathol (2011) 0.77
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27
Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med (2008) 9.20
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol (2008) 5.93
The international position on laparoscopic liver surgery: The Louisville Statement, 2008. Ann Surg (2009) 5.33
Resection of hepatocellular cancer ≤2 cm: results from two Western centers. Hepatology (2013) 5.05
Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis (2005) 4.51
Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology (2009) 4.50
Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res (2008) 4.35
Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology (2008) 4.03
Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology (2007) 3.85
The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res (2009) 3.18
Nomenclature of the finer branches of the biliary tree: canals, ductules, and ductular reactions in human livers. Hepatology (2004) 3.00
Robust cellular reprogramming occurs spontaneously during liver regeneration. Genes Dev (2013) 2.96
HGF, SDF-1, and MMP-9 are involved in stress-induced human CD34+ stem cell recruitment to the liver. J Clin Invest (2003) 2.89
Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology (2011) 2.66
Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol (2009) 2.42
Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology (2013) 2.42
Gene-expression signature of vascular invasion in hepatocellular carcinoma. J Hepatol (2011) 2.39
A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology (2006) 2.32
Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinoma. Hepatology (2004) 2.29
Liver transplantation for hepatocellular carcinoma: extension of indications based on molecular markers. J Hepatol (2008) 2.22
Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. Am J Gastroenterol (2003) 2.18
Inhibition of Foxo1 function is associated with improved fasting glycemia in diabetic mice. Am J Physiol Endocrinol Metab (2003) 2.06
Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation. J Hepatol (2006) 1.98
Strategies for the management of hepatocellular carcinoma. Nat Clin Pract Oncol (2007) 1.95
A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma. Gastroenterology (2009) 1.90
Improved insulin sensitivity is associated with restricted intake of dietary glycoxidation products in the db/db mouse. Diabetes (2002) 1.87
Liver fibrosis during an outbreak of acute hepatitis C virus infection in HIV-infected men: a prospective cohort study. J Infect Dis (2008) 1.78
MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. Gastroenterology (2011) 1.77
Hepatic resection for primary hepatolithiasis: a single-center Western experience. J Am Coll Surg (2012) 1.70
Posttransplant plasma cell hepatitis (de novo autoimmune hepatitis) is a variant of rejection and may lead to a negative outcome in patients with hepatitis C virus. Liver Transpl (2008) 1.68
IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. J Hepatol (2010) 1.66
Resection of hepatocellular carcinoma with macroscopic vascular invasion. Ann Surg Oncol (2013) 1.65
Beyond "cirrhosis": a proposal from the International Liver Pathology Study Group. Am J Clin Pathol (2012) 1.65
Pre-S2 deletion mutants of hepatitis B virus could have an important role in hepatocarcinogenesis in Asian children. Cancer Sci (2009) 1.61
Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. Ann Surg (2015) 1.53
Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials. Lancet Oncol (2002) 1.52
Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. Surgery (2004) 1.51
Hepatic stellate cells express functional CXCR4: role in stromal cell-derived factor-1alpha-mediated stellate cell activation. Hepatology (2009) 1.48
The beneficial impact of temporary porto-caval shunt in orthotopic liver transplantation: a single center analysis. Transpl Int (2010) 1.48
Intrahepatic cholangiocarcinoma: new insights in pathology. Semin Liver Dis (2011) 1.46
De novo hepatocellular carcinoma occurring in a transplanted liver: case report and review of the literature. Dig Dis Sci (2006) 1.45
Fulminant and fatal gas gangrene of the stomach in a healthy live liver donor. Liver Transpl (2004) 1.44
Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. Clin Cancer Res (2012) 1.44
Accelerated hepatitis C virus kinetics but similar survival rates in recipients of liver grafts from living versus deceased donors. Hepatology (2005) 1.44
Adult living donor liver transplantation for patients with hepatocellular carcinoma: extending UNOS priority criteria. Ann Surg (2004) 1.36
Retracted Metabolic basis of sexual dimorphism in PKU mice after genome-targeted PAH gene therapy. Mol Ther (2007) 1.25
Immunohistochemical evidence for hepatic progenitor cells in liver diseases. Liver (2002) 1.23
Dissecting EASL/AASLD Recommendations With a More Careful Knife: A Comment on "Surgical Misinterpretation" of the BCLC Staging System. Ann Surg (2015) 1.17
Post-liver transplant acute renal failure: factors predicting development of end-stage renal disease. Clin Transplant (2004) 1.17
Fibrolamellar carcinoma of the liver exhibits immunohistochemical evidence of both hepatocyte and bile duct differentiation. Mod Pathol (2010) 1.11
Feasibility and preliminary accuracy of high-resolution imaging of the liver and pancreas using FNA compatible microendoscopy (with video). Gastrointest Endosc (2012) 1.09
Spleens of myelofibrosis patients contain malignant hematopoietic stem cells. J Clin Invest (2012) 1.09
Intravascular epithelioid hemangioendothelioma of the inferior vena cava: case report of an unusual and unpredictable vascular tumor. Cardiovasc Pathol (2008) 1.09
Fifteen-year, single-center experience with the surgical management of intrahepatic cholangiocarcinoma: operative results and long-term outcome. Surgery (2007) 1.07
Morphologic features of extrahepatic manifestations of hepatitis C virus infection. Clin Dev Immunol (2012) 1.04
T cell targeting and phagocytosis of apoptotic biliary epithelial cells in primary biliary cirrhosis. J Autoimmun (2007) 1.03
Hilar cholangiocarcinoma involving the portal vein bifurcation: long-term results after resection. J Hepatobiliary Pancreat Surg (2002) 1.03
Predicting recurrence after liver transplantation in patients with hepatocellular carcinoma exceeding the up-to-seven criteria. Liver Transpl (2009) 1.02
Aggressive surgical resection for hilar cholangiocarcinoma: is it justified? Audit of a single center's experience. Am J Surg (2008) 1.02
Second hepatic resection for recurrent hepatocellular cancer: a Western experience. J Hepatol (2010) 1.00
Differences in surgical outcomes between hepatitis B- and hepatitis C-related hepatocellular carcinoma: a retrospective analysis of a single North American center. Ann Surg (2014) 0.99
Interferons alpha, beta, gamma each inhibit hepatitis C virus replication at the level of internal ribosome entry site-mediated translation. Liver Int (2005) 0.99
Importance of specimen size in accurate needle liver biopsy evaluation of patients with chronic hepatitis C. Clin Gastroenterol Hepatol (2005) 0.97
How should patients with hepatocellular carcinoma recurrence after liver transplantation be treated? J Hepatol (2005) 0.97
Thalidomide in advanced hepatocellular carcinoma with optional low-dose interferon-alpha2a upon progression. Oncologist (2005) 0.96
Hepatic cavernous hemangioma: underrecognized associated histologic features. Liver Int (2006) 0.95
Basal insulin gene expression significantly improves conventional insulin therapy in type 1 diabetic rats. Diabetes (2002) 0.95
Phase II trial of concurrent sunitinib and image-guided radiotherapy for oligometastases. PLoS One (2012) 0.95
Liver transplantation for neuroendocrine tumors. J Gastrointest Surg (2004) 0.93
Expression of human telomerase reverse transcriptase in regenerative and precancerous lesions of cirrhotic livers. Liver (2002) 0.92
Influenza vaccination in orthotopic liver transplant recipients: absence of post administration ALT elevation. Am J Transplant (2004) 0.91
Concurrent sunitinib and stereotactic body radiotherapy for patients with oligometastases: final report of a prospective clinical trial. Target Oncol (2013) 0.91
Cholangiolocellular carcinoma: an innocent-looking malignant liver tumor mimicking ductular reaction. Semin Liver Dis (2011) 0.91